Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Contineum Therapeutics has reported Total Non-Current Liabilities over the past 2 years, most recently at $14.8 million for Q4 2024.

  • Quarterly results put Total Non-Current Liabilities at $14.8 million for Q4 2024, up 164.32% from a year ago — trailing twelve months through Dec 2024 was $14.8 million (up 164.32% YoY), and the annual figure for FY2024 was $14.8 million, up 164.32%.
  • Total Non-Current Liabilities for Q4 2024 was $14.8 million at Contineum Therapeutics, up from $5.8 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CTNM hit a ceiling of $14.8 million in Q4 2024 and a floor of $3.9 million in Q2 2024.